Study to Test the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-onset Seizures in Adults With Drug-resistant Epilepsy
Public ClinicalTrials.gov record NCT03373383. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-Blind, Placebo-Controlled, Dose Finding Study to Evaluate the Efficacy and Safety of Padsevonil as Adjunctive Treatment of Focal-Onset Seizures in Adult Subjects With Drug-Resistant Epilepsy
Study identification
- NCT ID
- NCT03373383
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- UCB Biopharma S.P.R.L.
- Industry
- Enrollment
- 411 participants
Conditions and interventions
Conditions
Interventions
- Padsevonil Drug
- Placebo Other
Drug · Other
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 11, 2018
- Primary completion
- Jan 29, 2020
- Completion
- Jan 29, 2020
- Last update posted
- Dec 18, 2023
2018 – 2020
United States locations
- U.S. sites
- 27
- U.S. states
- 15
- U.S. cities
- 24
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ep0091 839 | Chandler | Arizona | 85226 | — |
| Ep0091 810 | Little Rock | Arkansas | 72205 | — |
| Ep0091 815 | La Jolla | California | 92037 | — |
| Ep0091 801 | San Francisco | California | 94115 | — |
| Ep0091 845 | Washington D.C. | District of Columbia | 20037 | — |
| Ep0091 809 | Ocala | Florida | 34471 | — |
| Ep0091 823 | Orlando | Florida | 32806 | — |
| Ep0091 825 | Port Charlotte | Florida | 33952 | — |
| Ep0091 820 | Tallahassee | Florida | 32308 | — |
| Ep0091 873 | Atlanta | Georgia | 30303 | — |
| Ep0091 803 | Honolulu | Hawaii | 96817 | — |
| Ep0091 832 | Peoria | Illinois | 61637 | — |
| Ep0091 822 | Baltimore | Maryland | 21287 | — |
| Ep0091 818 | Bethesda | Maryland | 20817 | — |
| Ep0091 817 | Saint Paul | Minnesota | 55102 | — |
| Ep0091 806 | Hackensack | New Jersey | 07601 | — |
| Ep0091 827 | New York | New York | 10016-48 | — |
| Ep0091 800 | Philadelphia | Pennsylvania | 19104 | — |
| Ep0091 802 | Philadelphia | Pennsylvania | 19107 | — |
| Ep0091 838 | Cordova | Tennessee | 38018 | — |
| Ep0091 835 | Nashville | Tennessee | 37232 | — |
| Ep0091 805 | Austin | Texas | 78701 | — |
| Ep0091 844 | Austin | Texas | 78758 | — |
| Ep0091 836 | Dallas | Texas | 75231 | — |
| Ep0091 830 | Dallas | Texas | 75390-91 | — |
| Ep0091 824 | Round Rock | Texas | 78681 | — |
| Ep0091 870 | San Antonio | Texas | 78229 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 121 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03373383, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 18, 2023 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03373383 live on ClinicalTrials.gov.